Arbutus Biopharma
ABUS
ABUS
72 hedge funds and large institutions have $86.5M invested in Arbutus Biopharma in 2019 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 23 increasing their positions, 18 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
72
Holders Change
+1
Holders Change %
+1.41%
% of All Funds
1.56%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
23
Reduced
18
Closed
7
Calls
$891K
Puts
$472K
Net Calls
+$419K
Net Calls Change
+$242K
Top Buyers
1 |
RI
RTW Investments
New York
|
+$4.2M |
2 |
![]()
JPMorgan Chase & Co
New York
|
+$2.74M |
3 |
Goldman Sachs
New York
|
+$477K |
4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$106K |
5 |
Geode Capital Management
Boston,
Massachusetts
|
+$96.8K |
Top Sellers
1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$3.97M |
2 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
-$2.78M |
3 |
Morgan Stanley
New York
|
-$428K |
4 |
BlackRock
New York
|
-$403K |
5 |
AQR Capital Management
Greenwich,
Connecticut
|
-$336K |